Close

AAMRI (AMRI) Enters License Agreement for CRISPR-Cas9 Gene Editing Technology

August 23, 2016 4:07 PM EDT Send to a Friend
AMRI (NASDAQ: AMRI) today announced that it entered into a non-exclusive commercial license agreement with the Broad Institute of MIT ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login